Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

DIVI'S LABORATORIES LTD. - 532488 - Intimation Of Date Of Annual General Meeting And Record Date

 We hereby inform that the 32nd Annual General Meeting (AGM) of the Company is scheduled to be held on Monday, August 22, 2022 at 10.00 A.M. IST through video conferencing (VC) / other audio-visual means (OAVM), in accordance with the applicable circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India. The Company has fixed Tuesday, August 16, 2022 as the 'Cut-off Date' for the purpose of determining the members eligible to vote on the resolutions set out in the Notice of the AGM or to attend the AGM. The Company has fixed Friday, August 12, 2022 as the 'Record Date' for the purpose of determining the Members eligible to receive dividend for the financial year 2021-22, if approved at the AGM.
04-07-2022
Bigul

DIVI'S LABORATORIES LTD. - 532488 - Closure of Trading Window

 Pursuant to the Company's Code of Conduct for Prevention of Insider Trading (the Code), we hereby inform that the Trading Window for trading in securities of the Company will remain closed for all Designated Persons and their Immediate Relatives, as well as Insiders covered under the Code, from July 01, 2022 till 48 hours after the declaration of Unaudited Financial Results for the first quarter ending on June 30, 2022. The date of Board Meeting for declaration of the financial results of the Company for the first quarter ending on June 30, 2022 will be intimated in due course. This is for your information and records.
30-06-2022
Bigul

DIVI'S LABORATORIES LTD. - 532488 - Submission Of Half Yearly Disclosure On Related Party Transactions For The Half Year Ended March 31, 2022

 Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we enclose disclosure of Related Party Transactions in the format specified under SEBI Circular bearing reference no. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated November 22, 2021, for the half year ended March 31, 2022. This is for your information and records.
01-06-2022
Bigul

DIVI'S LABORATORIES LTD. - 532488 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Please find enclosed copies of newspaper advertisement regarding 'Notice to Shareholders' of the Company intimating that equity shares in respect of which dividend remain unclaimed for seven consecutive years would be transferred to Investor Education and Protection Fund (IEPF) Authority. The newspaper advertisements are published on May 31, 2022 in Financial Express (English daily) all editions and Andhra Prabha (Telugu daily) Hyderabad edition. The advertisements may also be accessed on the website of the Company at www.divislabs.com. This is for your information and records.
31-05-2022
Bigul

DIVI'S LABORATORIES LTD. - 532488 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

 We are herewith enclosing copy of the transcript of the Company's earnings conference call for Q4 and full year FY22, held on May 23, 2022. This transcript is also uploaded on our website www.divislabs.com under Investor Relations section. This is for your information and records.
26-05-2022

Divis Labs Consolidated March 2022 Net Sales at Rs 2,518.44 crore, up 40.84% Y-o-Y

 NULL
24-05-2022
Bigul

DIVI'S LABORATORIES LTD. - 532488 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and further to our intimation letter dated May 16, 2022, we hereby inform that the audio recording of the earnings call for the quarter and financial year ended March 31, 2022, held on May 23, 2022, at 14.00 Hrs IST have been uploaded on our website at the following weblink: https://www.divislabs.com/wp-content/uploads/2022/05/DIV0320220523141281.mp3 This is for your information and records.
23-05-2022

Earnings Call for Q4FY22 of Divi's Laboratories

 Conference Call with Divi's Laboratories Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript.
23-05-2022

Pharma stock recommends dividend of 30. Details here

 Divis Labs said that the record date for the purpose of the payment of dividend will be informed in due course
23-05-2022
Bigul

Q4FY22 Quarterly Result Announced for Divi's Laboratories Ltd.

 Pharmaceuticals firm Divi's Laboratories declares Q4FY22 result: Divi's Labs earns a Revenue of Rs 9074 crores for FY22 on a consolidated basis. Divi's Laboratories has earned a consolidated total revenue of Rs 9074 crores for the financial year 2021-22 as against Rs 7032 crores during the previous year, reflecting a growth of 29%. PBT for the current year grew by 38% to Rs 3684 crores as against a PBT of Rs 2666 crores for the previous year. PAT for the year amounted to Rs 2960 crores as against a PAT of Rs 1984 crores for the last year, reflecting a growth of 49%. Result PDF
23-05-2022
Next Page
Close

Let's Open Free Demat Account